Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
4.320
-0.090 (-2.04%)
At close: Apr 28, 2026, 4:00 PM EDT
4.250
-0.070 (-1.62%)
After-hours: Apr 28, 2026, 7:24 PM EDT
Outset Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Outset Medical stock have an average target of 13.33, with a low estimate of 8.00 and a high estimate of 17. The average target predicts an increase of 208.56% from the current stock price of 4.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 12, 2026.
Analyst Ratings
The average analyst rating for Outset Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $17 → $15 | Strong Buy | Maintains | $17 → $15 | +247.22% | Feb 12, 2026 |
| Stifel | Stifel | Strong Buy Maintains $14 → $8 | Strong Buy | Maintains | $14 → $8 | +85.19% | Jan 7, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +293.52% | Dec 16, 2025 |
| Stifel | Stifel | Strong Buy Maintains $17 → $14 | Strong Buy | Maintains | $17 → $14 | +224.07% | Nov 11, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $17 | Hold | Maintains | $22 → $17 | +293.52% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
130.57M
from 119.48M
Increased by 9.29%
Revenue Next Year
144.92M
from 130.57M
Increased by 10.99%
EPS This Year
-2.92
from -5.37
EPS Next Year
-2.42
from -2.92
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 134.1M | 150.6M | |||||
| Avg | 130.6M | 144.9M | |||||
| Low | 122.6M | 136.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 12.2% | 15.3% | |||||
| Avg | 9.3% | 11.0% | |||||
| Low | 2.6% | 4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -2.90 | -2.21 | |||||
| Avg | -2.92 | -2.42 | |||||
| Low | -2.87 | -2.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.